Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | KLF10 | Q13118 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23521674 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30788068 | 1.00 | SLC6A2 (0.50) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6712642 | 0.86 | SLC6A4 (0.65) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6712640 | 0.86 | SLC6A4 (0.65) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5869202 | 0.86 | SLC6A4 (0.65) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL23761083 | 0.81 | SLC6A2 (0.50) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL23521649 | 0.81 | SLC6A2 (0.50) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29975150 | 0.81 | SLC6A2 (0.50) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL23521650 | 0.81 | SLC6A2 (0.50) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21742919 | 0.80 | KCNA3 (0.34) | SLC6A2SLC6A4HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119375-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20220119375-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3838900-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2021-06-23 | — | — | EP | disclosed |
| EP-3838900-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020035070-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | 漳州片仔癀药业股份有限公司 | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119375-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | TRPV1, TRPA1, TRPC7 | SLC6A2 335/4885SLC6A4 172/4885CYP1A2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.